Aktienanalyse zu Biomerica Inc (BMRA)BMRABiomerica Inc

Biomerica, Inc. is a biomedical technology company. The Company develops, patents, manufactures and markets advanced diagnostic and therapeutic products. Its diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients in the diagnosis of various diseases, food intolerances, and other medical complications. The Company’s diagnostic test kits can also be used to measure or detect the presence and levels of specific bacteria, hormones, antibodies, antigens and other substances, which may exist in the human body in small concentrations. Its range of medical diagnostic products is sold in two markets: clinical laboratories and point-of-care settings. The Company’s diagnostic-guided therapy (DGT) product is developed on the inFoods technology platform, which is designed to aid in the management of gastrointestinal conditions such as irritable bowel syndrome (IBS) and other inflammatory diseases. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Given the current price of $1.61 and the RSI at 25.085, which indicates the stock is oversold, it may seem like a potential buy. However, the company's financials show a troubling trend with a net loss of $1.14 million in Q4 and a year-to-date change of -36.36%. The risks are high, particularly with a forward P/E of 0, indicating no expected earnings growth, and a significant insider dilution of 30.4% from recent financing. Therefore, I recommend selling as the financial instability and declining revenue outweigh the potential for recovery.

1 analysts cover BMRA: 1 rate it Buy, 0 Hold and 0 Sell.